0%
Print report
Variant interpretation report

APC c.8462A>G, p.Asp2821Gly

NM_001127510.3:c.8462A>G NP_001120982.1:p.(Asp2821Gly) Missense · exon 17 View identifiers
Classification
Likely benign

Variant description:

The APC NM_001127510.3:c.8462A>G (NP_001120982.1:p.(Asp2821Gly)) missense variant has previously been reported in somatic cancers (COSMIC; COSV57360049, n = 1 time). Based on available guidelines, this variant is considered to be Likely Benign.

Five-step scale from benign to pathogenic. This variant is likely benign. Select a step to read what it means.

Likely benign.A likely benign classification under the recorded framework.

In plain language

Gene-level background from the recorded interpretation.

About APC

APC is a tumor suppressor gene whose protein acts as a key brake on the Wnt signaling pathway by helping mark the growth-promoting protein beta-catenin for destruction; it also participates in cell migration, adhesion, and apoptosis. Inherited mutations in APC cause familial adenomatous polyposis (FAP), an autosomal dominant condition characterized by numerous colorectal polyps and a very high risk of colorectal cancer, with related forms including attenuated FAP and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS). Somatic APC mutations are found in roughly 50-80% of sporadic colorectal cancers, where they act as early tumor-initiating events, and are also observed in some breast, stomach, and prostate cancers. Loss of APC function leaves Wnt signaling abnormally active, driving uncontrolled cell growth, which makes APC a central tumor suppressor in colorectal cancer.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is ClinGen APC VCEP v2.1. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 0 Benign evidence criteria: 2
Pathogenic criteria applied · 0

No pathogenic criterion marked as applied in the recorded assessment.

Benign criteria applied · 2
BS1Strong
BS1 · strong

Met, Strong: gnomAD v2.1 non-cancer Popmax Filtering Allele Frequency is 0.017773%, exceeding the APC VCEP's ≥0.001% BS1 threshold.

BP1Supporting
BP1 · supporting

Met at supporting: p.(Asp2821Gly) is a missense variant at residue 2821, outside the BP1 exception covering APC codons 1021-1035.

Recorded classification: Likely benign

Likely Benign: BS1 (strong) alone satisfies the APC VCEP's Rule26; BP1 (supporting) is also applied.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
50 / 1,604,312 alleles

gnomAD v4.1: 50 / 1,604,312 alleles. Recorded AF 3.1166e-05. Recorded homozygote count 0.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 3.68259e-05; MAF= 0.00368%, 10/271548 alleles, homozygotes = 0) and has highest observed frequency in the African/African American population (AF= 0.000363666; MAF= 0.03637%, 9/24748 alleles, homozygotes = 0); grpmax FAF= 0.00020406.

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 0.00010857763300760044, 2/18420 alleles, homozygotes = 0).

No screenshot for this evidence
REVEL score
0.226 recorded score

Recorded REVEL score: 0.226. Refer to the recorded PP3/BP4 rationale for interpretation.

No listed criterion applied
ClinVar submissions
11 reported laboratory submissions

7 Likely benign · 2 Uncertain significance · 1 Uncertain Significance · 1 Benign. ClinVar API review status: criteria provided, conflicting classifications.

Context only ClinVar ↗
Functional evidence
Statement recorded

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
1 recorded samples

This variant has previously been reported in somatic cancers (COSMIC; COSV57360049, n = 1 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under ClinGen APC VCEP v2.1, with the data and sources behind each one.

28 criteria with recorded statuses: 2 met · 5 not met · 10 not assessed · 11 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

The APC VCEP governs all five requested criteria; PP4, PP5, and BP6 are explicitly not usable, BP5 requires an undocumented alternate genetic basis with colorectal polyposis, and PS4 lacks variant-specific phenotype-point or case-control data.

The three requested variant notations were searched in both governing APC VCEP full-text files; no matching entry was found.

PP3 was not assessed because the VCEP-directed multi-predictor splice evaluation is incomplete; the available SpliceAI result is non-deleterious with max delta score 0.00.

BP4 and BP7 are not applicable because the variant is missense, not synonymous or intronic.

Met · 2

BS1 StrongVCEPMet, Strong: gnomAD v2.1 non-cancer Popmax Filtering Allele Frequency is 0.017773%, exceeding the APC VCEP's ≥0.001% BS1 threshold. Details ▾Hide ▴
Reasoning

The APC VCEP specifies BS1 at allele frequency ≥ 0.001%, preferably using the Popmax Filtering Allele Frequency from the gnomAD v2.1.1 non-cancer dataset. The variant's gnomAD v2.1 non-cancer Popmax Filtering Allele Frequency is 0.00017773 (0.017773%), exceeding 0.00001 (0.001%), so BS1 is met at Strong strength.

VCEP rule
Allele frequency ≥ 0.001% (preferably based on the Popmax Filtering Allele Frequency of the non-cancer dataset from gnomAD (v2.1.1))
Evidence considered
  • APC VCEP supplementary specifications, BS1 row: allele frequency ≥ 0.001%, preferably based on the Popmax Filtering Allele Frequency of the non-cancer dataset from gnomAD v2.1.1.
  • GNOMAD_V2_1_NON_CANCER: gnomAD v2.1 non-cancer exomes, 7/225626 alleles, AF 3.10248e-05 (0.00310%), homozygotes 0; Popmax Filtering Allele Frequency 0.00017773 (0.017773%).
Still missing
  • No variant-specific entry for c.8462A>G, p.Asp2821Gly, or p.D2821G was found in APC_specifications_supplementary-material_V2.pdf.txt.
Sources
BP1 SupportingVCEPMet at supporting: p.(Asp2821Gly) is a missense variant at residue 2821, outside the BP1 exception covering APC codons 1021-1035. Details ▾Hide ▴
Reasoning

The assessed variant is a missense variant, p.(Asp2821Gly), in APC. The APC VCEP permits BP1 for APC missense variants except those in the first 15-amino-acid repeat of the β-catenin binding domain, codons 1021-1035. Residue 2821 is outside that exception, so BP1 is met at Supporting strength.

VCEP rule
APC is a gene for which primarily truncating variants are known to cause disease. Based on our knowledge there are only two amino acid positions (1026 and 1028), where reported missense variants can be classified as Likely Pathogenic based on the APC-specific criteria (c.3077A>G p.(Asn1026Ser) and c.3084T>A p.(Ser1028Arg)) (for details see PS1). Therefore, for all variants located in the first 15-amino acid repeat of the β-catenin binding domain (codon 1021-1035) BP1 is not allowed to be used.
Evidence considered
  • APC VCEP BP1 rule: BP1 is applicable to APC except for missense variants located in codons 1021-1035, the first 15-amino-acid repeat of the β-catenin binding domain.
  • Case normalization identifies the variant as missense p.(Asp2821Gly) at residue 2821, outside codons 1021-1035.
  • The APC VCEP states that APC is a gene for which primarily truncating variants are known to cause disease.
Still missing
  • No entry for c.8462A>G, p.Asp2821Gly, or p.D2821G was found in APC_specifications_supplementary-material_V2.pdf.txt.
Sources

Not met · 5 · evaluated, threshold not reached

PS1 VCEPNot met: p.(Asp2821Gly) affects residue 2821, outside the APC VCEP's only eligible missense PS1 positions, 1026 and 1028. Details ▾Hide ▴
Reasoning

The APC VCEP limits missense PS1_Moderate to residues 1026 and 1028, where the only currently recognized Likely Pathogenic APC missense variants are c.3077A>G p.(Asn1026Ser) and c.3084T>A p.(Ser1028Arg). NM_001127510.3:c.8462A>G produces p.(Asp2821Gly) at residue 2821, not either specified residue, and the VCEP states that no missense variant has been classified as Pathogenic based on current evidence. Therefore neither the strong same-amino-acid Pathogenic route nor the moderate same-amino-acid Likely Pathogenic route applies.

VCEP rule
Based on the current knowledge there are only two amino acid positions (1026 and 1028), where reported missense variants can be classified as Likely Pathogenic based on the APC-specific criteria (c.3077A>G p.(Asn1026Ser) and c.3084T>A p.(Ser1028Arg)) , located in the first 15-amino acid repeat of the β-catenin binding domain (codon 1021-1035). Thus, PS1_Moderate can currently only be used for missense variants at these two amino acid positions.
Evidence considered
  • APC VCEP PS1 specification: only amino-acid positions 1026 and 1028 have reported missense variants classifiable as Likely Pathogenic under APC-specific criteria; PS1_Moderate can currently only be used at those positions.
  • Case normalization identifies NM_001127510.3:c.8462A>G as NP_001120982.1:p.(Asp2821Gly), residue 2821.
  • No VCEP-established Pathogenic or Likely Pathogenic same-amino-acid comparator for p.(Asp2821Gly) is documented in the governing specification.
Still missing
  • No entry for c.8462A>G, p.Asp2821Gly, or p.D2821G was found in APC_specifications_supplementary-material_V2.pdf.txt; the conclusion is based on the VCEP's general position-specific rule.
Sources
PM2 VCEPNot met: gnomAD v2.1 non-cancer exomes show AF 0.00310% with AC 7, exceeding the APC VCEP's ≤0.0003% PM2 threshold. Details ▾Hide ▴
Reasoning

The APC VCEP defines PM2 Supporting as allele frequency ≤0.0003% when allele count is >1, or <0.001% when allele count is ≤1, using the total population of the gnomAD v2.1.1 non-cancer dataset. The specified exome-only non-cancer record has AC 7 and AF 3.10248e-05 (0.00310%), exceeding the ≤0.000003 threshold; PM2 is not met.

VCEP rule
The allele frequency ≤ 0.0003% (0.000003) is used if the allele count is > 1. To tolerate the occurrence 1 x in gnomAD the VCEP has set an allele frequency < 0.001% (0.00001) (which is below BS1) if the allele count is ≤ 1.
Evidence considered
  • APC VCEP supplementary specifications, PM2 row: total population from the non-cancer dataset from gnomAD v2.1.1 is recommended for allele frequency determination.
  • APC VCEP supplementary specifications, PM2 calculation: prevalence 1:10,000, penetrance 0.9, calculated allele frequency ≤0.0003%; use ≤0.0003% when allele count is >1 and <0.001% when allele count is ≤1.
  • GNOMAD_V2_1_NON_CANCER: specified exome-only figures show AC 7, AN 225626, AF 3.10248e-05 (0.00310%), homozygotes 0.
Still missing
  • No variant-specific entry for c.8462A>G, p.Asp2821Gly, or p.D2821G was found in APC_specifications_supplementary-material_V2.pdf.txt.
Sources
PM5 VCEPNot met: residue 2821 is outside the APC VCEP's PM5-eligible residues 1026 and 1028, and zero same-residue comparator candidates were identified. Details ▾Hide ▴
Reasoning

The APC VCEP restricts PM5 to missense variants at residues 1026 and 1028, where the reported comparator variants are c.3077A>G p.(Asn1026Ser) and c.3084T>A p.(Ser1028Arg), classified as Likely Pathogenic under APC-specific criteria. The assessed variant is p.(Asp2821Gly) at residue 2821, so it is outside the VCEP-defined PM5 positions. The same-residue candidate collection found zero same-residue candidates, but the VCEP's explicit position restriction is decisive.

VCEP rule
Do not use if the mechanism of pathogenicity for the reported variant is a splicing defect. Multiple in silico splicing predictors1 should be applied to the reported variant or the splicing defect was confirmed by RNA analysis. In this case check, if PS1 or PS1_Moderate is applicable. Based on the current knowledge this criterion can only be used for missense variants at the two amino acid positions 1026 and 1028, where reported missense variants can be classified as Likely Pathogenic based on the APC-specific criteria (c.3077A>G p.(Asn1026Ser) and c.3084T>A p.(Ser1028Arg)) (for details see PS1).
Evidence considered
  • APC VCEP PM5 specification: this criterion can only be used for missense variants at residues 1026 and 1028, with the two listed Likely Pathogenic APC missense variants as comparators.
  • Case normalization identifies p.(Asp2821Gly) at residue 2821.
  • pm5_candidates.json reports total_candidates_seen=4, same_residue_candidates=0, expert_panel_plp_candidates=0, and non_expert_majority_plp_candidates=0.
Still missing
  • No entry for c.8462A>G, p.Asp2821Gly, or p.D2821G was found in APC_specifications_supplementary-material_V2.pdf.txt.
  • The PM5 candidate search recorded an HTTP 429 error; no same-residue candidate was nevertheless identified, and the VCEP's explicit residue restriction determines the result.
Sources
BA1 VCEPNot met: gnomAD v2.1 non-cancer Popmax Filtering Allele Frequency is 0.017773%, below the APC VCEP's ≥0.1% BA1 threshold. Details ▾Hide ▴
Reasoning

The APC VCEP specifies BA1 when the allele frequency is ≥ 0.1%, preferably using the Popmax Filtering Allele Frequency from the gnomAD v2.1.1 non-cancer dataset. The variant has gnomAD v2.1 non-cancer exome AC 7/225626 and Popmax Filtering Allele Frequency 0.00017773 (0.017773%), which is below 0.001 and therefore does not meet BA1.

VCEP rule
Allele frequency ≥ 0.1% (preferably based on the Popmax Filtering Allele Frequency of the non-cancer dataset from gnomAD (v2.1.1))
Evidence considered
  • APC VCEP supplementary specifications, BA1 row: allele frequency ≥ 0.1%, preferably based on the Popmax Filtering Allele Frequency of the non-cancer dataset from gnomAD v2.1.1.
  • GNOMAD_V2_1_NON_CANCER: gnomAD v2.1 non-cancer exomes, 7/225626 alleles, AF 3.10248e-05 (0.00310%), homozygotes 0; Popmax Filtering Allele Frequency 0.00017773 (0.017773%).
Still missing
  • No variant-specific entry for c.8462A>G, p.Asp2821Gly, or p.D2821G was found in APC_specifications_supplementary-material_V2.pdf.txt.
Sources
BS2 VCEPNot met: gnomAD v2.1 non-cancer exomes report zero homozygotes, and no qualifying healthy-individual phenotype points are available. Details ▾Hide ▴
Reasoning

The APC VCEP specifies BS2 Strong for ≥10 healthy-individual points or ≥2 observations in the homozygous state. The gnomAD v2.1 non-cancer exome record reports 0 homozygotes, and no qualifying individual-level healthy-person phenotype data are available; neither BS2 path is met.

VCEP rule
≥ 10 points for healthy individuals **OR** ≥ 2 times in homozygous state.
Evidence considered
  • APC VCEP supplementary specifications, BS2 row: the non-cancer gnomAD v2.1.1 dataset can be used to search for homozygous individuals, but cannot establish heterozygous healthy individuals because of limited phenotype information.
  • CSPEC BS2 criterion entry: ≥ 10 points for healthy individuals OR ≥ 2 times in homozygous state.
  • GNOMAD_V2_1_NON_CANCER: gnomAD v2.1 non-cancer exomes report 0 homozygotes for 7/225626 variant alleles.
Still missing
  • No variant-specific entry for c.8462A>G, p.Asp2821Gly, or p.D2821G was found in APC_specifications_supplementary-material_V2.pdf.txt.
  • No individual-level age, colonoscopy, adenoma, or phenotype data are available to accumulate healthy-individual points.
Sources

Not assessed · 10 · no assessment recorded

PS2 VCEPNot assessed: no proband-level de novo score, parental testing, or phenotype-point assignment is available for this variant. Details ▾Hide ▴
Reasoning

The APC VCEP assigns PS2 from de novo scores curated using Tables 1 and 2, with confirmed parental relationships required for the higher score. The available case evidence contains no proband-level de novo observation, phenotype-point assignment, parental testing result, confirmed parental relationship, or de novo score for NM_001127510.3:c.8462A>G (p.Asp2821Gly; p.D2821G). Searches of APC_specifications_supplementary-material_V2.pdf.txt and Table-1%262.pdf.txt found no entry for c.8462A>G, p.Asp2821Gly, or p.D2821G. PS2 cannot therefore be evaluated under the VCEP rule.

VCEP rule
≥ 4 _de novo_ scores. For curation of _de novo_ score see **Tables 1** and **2**. ... 2-3.5 _de novo_ scores. For curation of _de novo_ score see **Tables 1** and **2**. ... 1-1.5 _de novo_ score. For curation of _de novo_ score see **Tables 1** and **2**.
Evidence considered
  • The case bundle contains no proband-level de novo result, parental testing result, confirmed parental relationship, phenotype-point score, or de novo score for NM_001127510.3:c.8462A>G.
  • APC_specifications_supplementary-material_V2.pdf.txt was searched for c.8462A>G, p.Asp2821Gly, and p.D2821G; no variant-specific entry was found.
  • Table-1%262.pdf.txt was searched for c.8462A>G, p.Asp2821Gly, and p.D2821G; no variant-specific entry was found.
Still missing
  • No documented de novo observation for NM_001127510.3:c.8462A>G.
  • No parental testing or confirmed parental relationship is documented.
  • No APC phenotype-point assignment for the proband is documented.
  • No entry for c.8462A>G, p.Asp2821Gly, or p.D2821G was found in APC_specifications_supplementary-material_V2.pdf.txt.
  • No entry for c.8462A>G, p.Asp2821Gly, or p.D2821G was found in Table-1%262.pdf.txt.
Sources
PS3 VCEPNot assessed: no variant-specific qualifying RNA assay was found, and the VCEP protein-assay pathway is limited to APC codons 959-2129 while this variant affects codon 2821. Details ▾Hide ▴
Reasoning

The APC VCEP PS3 rule permits pathogenic functional evidence only when the specified RNA findings are demonstrated, or when a protein assay shows increased beta-catenin-regulated transcription activity and/or decreased beta-catenin binding by surface plasmon resonance for variants within APC codons 959-2129. This variant is missense p.(Asp2821Gly) in exon 17, outside codons 959-2129. The searched APC VCEP supplementary file contains no entry for c.8462A>G, p.Asp2821Gly, or p.D2821G, and the available paper extracts report no variant-specific functional assay for this variant. Therefore, PS3 cannot be evaluated from the available VCEP-governed evidence.

VCEP rule
**RNA assays** show 1. inframe skipping of exons other than exon 13 or 14 AND reports of exon deletion/skipping/loss, insertion of intronic nucleotides **OR** 2. over-expression of an alternative transcript (exons 10, 11 or 15) **Protein assays** show Increased β-catenin regulated transcription activity and/or decreased binding to β-catenin by surface plasmon resonance (only for variants within the β-catenin binding domain, which refers to codons 959-2129 of _APC_) [Reference 2].
Evidence considered
  • ClinGen InSiGHT APC VCEP CSPEC PS3 Supporting rule: qualifying evidence requires specified RNA findings or increased beta-catenin-regulated transcription activity and/or decreased beta-catenin binding by surface plasmon resonance, with the protein path restricted to APC codons 959-2129.
  • Case normalization identifies NM_001127510.3:c.8462A>G as NP_001120982.1:p.(Asp2821Gly), a missense variant in exon 17, codon 2821.
  • APC_specifications_supplementary-material_V2.pdf.txt was searched for c.8462A>G, p.Asp2821Gly, and p.D2821G; no matching variant entry was found.
  • PMID:25741868 paper extract: general ACMG/AMP framework with no APC c.8462A>G or p.(D2821G) and no variant-specific functional result.
  • PMID:26580448 paper extract: APC was analyzed in a pediatric cancer cohort, but the paper does not explicitly mention APC c.8462A>G or p.(D2821G) and provides no variant-specific functional assay.
Still missing
  • No entry for c.8462A>G, p.Asp2821Gly, or p.D2821G was found in APC_specifications_supplementary-material_V2.pdf.txt.
  • No variant-specific qualifying RNA or protein functional assay was identified in the available evidence or paper extracts.
Sources
PS4 VCEPNot assessed: no variant-specific phenotype points, affected-case counts, or control comparison are available to apply the APC VCEP PS4 thresholds. Details ▾Hide ▴
Reasoning

The APC VCEP assigns PS4 from phenotype points: ≥16 points is Very Strong, 4-15.5 Strong, 2-3.5 Moderate, and 1-1.5 Supporting, with phenotype points curated from Table 1. The searched APC VCEP files APC_specifications_supplementary-material_V2.pdf.txt and Table-1%262.pdf.txt contain no entry for c.8462A>G, p.Asp2821Gly, or p.D2821G. The literature packet has no ai_classified_papers; the available full-text extract for PMID:26580448 does not mention this exact variant and reports only six pathogenic/probably pathogenic APC mutations in a pediatric cohort, without variant-specific case counts, controls, segregation, or phenotype-point data. Therefore the VCEP PS4 strength cannot be determined from the available evidence.

VCEP rule
≥ 16 phenotype points. For phenotype points curation see **Table 1**. ... 4-15.5 phenotype points. For phenotype points curation see **Table 1**. ... 2-3.5 phenotype points. For phenotype points curation see **Table 1**. ... 1-1.5 phenotype point. For phenotype points curation see **Table 1**.
Evidence considered
  • APC VCEP CSPEC PS4 strength rules: ≥16 phenotype points = Very Strong; 4-15.5 = Strong; 2-3.5 = Moderate; 1-1.5 = Supporting.
  • APC_specifications_supplementary-material_V2.pdf, PS4 row: the modification is based on Fortuno et al. 2020 (PMID:33300245).
  • Table-1%262.pdf, Table 1: phenotype points are 1 for highly specific APC phenotypes and 0.5 for phenotypes consistent with APC but not highly specific.
  • PMID:26580448 full-text extract: APC mutations occurred in 6 patients in the cohort, but c.8462A>G/p.D2821G was not mentioned and no variant-specific phenotype or control comparison was provided.
  • The exact variant notations c.8462A>G, p.Asp2821Gly, and p.D2821G were searched in both governing APC VCEP full-text files without a match.
Still missing
  • No entry for c.8462A>G, p.Asp2821Gly, or p.D2821G was found in APC_specifications_supplementary-material_V2.pdf.txt.
  • No entry for c.8462A>G, p.Asp2821Gly, or p.D2821G was found in Table-1%262.pdf.txt.
  • Variant-specific affected-patient phenotype data and case-control counts or a matched-ancestry control frequency are unavailable.
  • The literature_pass.json packet has an empty ai_classified_papers list; PMID:26580448 was checked and does not report this exact variant.
Sources
PM6 VCEPNot assessed: no assumed-de-novo score, proband phenotype points, or parental-relationship evidence is available for this variant. Details ▾Hide ▴
Reasoning

The APC VCEP assigns PM6 from de novo scores curated using Tables 1 and 2, including assumed de novo evidence without confirmed parental relationships. The available case evidence contains no proband-level de novo observation, phenotype-point assignment, parental testing result, or de novo score for NM_001127510.3:c.8462A>G (p.Asp2821Gly; p.D2821G). Searches of APC_specifications_supplementary-material_V2.pdf.txt and Table-1%262.pdf.txt found no entry for c.8462A>G, p.Asp2821Gly, or p.D2821G. PM6 cannot therefore be evaluated under the VCEP rule.

VCEP rule
2-3.5 _de novo_ scores. For curation of _de novo_ score see **Tables 1** and **2**. ... 1-1.5 _de novo_ scores. For curation of _de novo_ score see **Tables 1** and **2**. ... 0.5 _de novo_ scores. For curation of _de novo_ score see **Tables 1** and **2**.
Evidence considered
  • The case bundle contains no proband-level de novo result, parental testing result, phenotype-point score, or de novo score for NM_001127510.3:c.8462A>G.
  • APC_specifications_supplementary-material_V2.pdf.txt was searched for c.8462A>G, p.Asp2821Gly, and p.D2821G; no variant-specific entry was found.
  • Table-1%262.pdf.txt was searched for c.8462A>G, p.Asp2821Gly, and p.D2821G; no variant-specific entry was found.
Still missing
  • No documented assumed-de-novo observation for NM_001127510.3:c.8462A>G.
  • No proband phenotype-point assignment is documented.
  • No parental relationship or parental testing information is documented.
  • No entry for c.8462A>G, p.Asp2821Gly, or p.D2821G was found in APC_specifications_supplementary-material_V2.pdf.txt.
  • No entry for c.8462A>G, p.Asp2821Gly, or p.D2821G was found in Table-1%262.pdf.txt.
Sources
PP1 VCEPNot assessed: no segregating relatives, family count, or qualifying meioses are documented for this variant. Details ▾Hide ▴
Reasoning

The APC VCEP requires documented segregation across qualifying meioses and families for PP1 strength assignment. The available case evidence contains no segregating relatives, family count, meiosis count, genotype-phenotype observations, or non-segregation analysis for NM_001127510.3:c.8462A>G (p.Asp2821Gly; p.D2821G). The VCEP files contain no variant-specific entry under any of the searched notations. PP1 cannot therefore be evaluated under the VCEP rule.

VCEP rule
Variant segregates in ≥ 7 meioses in ≥ 2 families. ... Variant segregates in 5-6 meioses in ≥ 1 family. ... Variant segregates in 3-4 meioses in ≥ 1 family.
Evidence considered
  • The case bundle contains no family segregation observations, affected-relative genotypes, family count, or meiosis count for NM_001127510.3:c.8462A>G.
  • APC_specifications_supplementary-material_V2.pdf.txt was searched for c.8462A>G, p.Asp2821Gly, and p.D2821G; no variant-specific entry was found.
  • Table-1%262.pdf.txt was searched for c.8462A>G, p.Asp2821Gly, and p.D2821G; no variant-specific entry was found.
Still missing
  • No family segregation data are documented.
  • No meiosis count is documented.
  • No affected-relative genotype and phenotype data are documented.
  • No entry for c.8462A>G, p.Asp2821Gly, or p.D2821G was found in APC_specifications_supplementary-material_V2.pdf.txt.
  • No entry for c.8462A>G, p.Asp2821Gly, or p.D2821G was found in Table-1%262.pdf.txt.
Sources
PP3 VCEPNot assessed: SpliceAI max delta score is 0.00, but the VCEP-directed multi-predictor splice evaluation lacks a MaxEntScan result. Details ▾Hide ▴
Reasoning

The APC VCEP limits missense computational evidence by excluding conservation/evolutionary models and directing use of in silico splicing predictors for presumed missense variants. The variant is a missense SNV, NM_001127510.3:c.8462A>G, p.(Asp2821Gly), so PP3 is within scope only for possible splice impact. The available SpliceAI result has DS_AG=0.00, DS_AL=0.00, DS_DG=0.00, DS_DL=0.00 and max delta score=0.00, which does not support a deleterious splice effect. However, the APC supplementary material identifies SpliceAI and MaxEntScan as the recommended splice prediction programs and the available case evidence contains no MaxEntScan result or multiple-predictor deleterious result. Therefore the VCEP computational splice-evidence requirement cannot be fully evaluated; no missense protein-impact predictor was used because the VCEP excludes those models for this purpose.

VCEP rule
**Missense variants:** Do not use computational prediction models for conservation, evolution, etc. _In silico_ splicing predictors should be used for presumed missense variants to reveal possible splicing effects.
Evidence considered
  • APC VCEP PP3 rule in cspec: for missense variants, do not use conservation/evolutionary computational models; use in silico splicing predictors for presumed missense variants to reveal possible splicing effects.
  • Case variant normalization: NM_001127510.3:c.8462A>G, NP_001120982.1:p.(Asp2821Gly), VEP consequence missense_variant.
  • SpliceAI Lookup result for NM_001127510.3:c.8462A>G: DS_AG=0.00, DS_AL=0.00, DS_DG=0.00, DS_DL=0.00, max delta score=0.00; the result predicts no significant splice impact.
  • APC_specifications_supplementary-material_V2.pdf, PP3 section and footnote 1: the VCEP directs use of splice prediction programs, including SpliceAI and MaxEntScan; only SpliceAI is available in the case evidence.
Still missing
  • The APC_specifications_supplementary-material_V2.pdf file was searched for c.8462A>G, p.Asp2821Gly, and p.D2821G; no variant-specific entry was found.
  • No MaxEntScan result or other second VCEP-recommended splice-predictor result is available for this variant.
Sources
BS3 VCEPNot assessed: no qualifying RNA or protein assay showing preserved function was found, and the VCEP protein-assay pathway excludes this codon 2821 variant outside APC residues 959-2129. Details ▾Hide ▴
Reasoning

The APC VCEP BS3 rule requires either a qualifying RNA assay showing no mRNA aberration or a protein assay showing retention of beta-catenin-regulated transcription activity comparable to wild type, with the protein pathway limited to APC codons 959-2129. This variant is missense p.(Asp2821Gly) at codon 2821, outside that domain. The searched APC VCEP supplementary file contains no entry for c.8462A>G, p.Asp2821Gly, or p.D2821G, and the available paper extracts contain no variant-specific functional assay or benign functional result. Therefore, BS3 cannot be evaluated from the available VCEP-governed evidence.

VCEP rule
**RNA assay** of a synonymous or intronic variant in constitutional patient sample demonstrates no mRNA aberration, without demonstration of biallelic expression or use of nonsense-mediated decay inhibition **OR** **Protein assay** show retention of β-catenin regulated transcription activity comparable to wild-type (only for variants within the β-catenin binding domain, which refers to codons 959-2129 of _APC_, see PMID: 33348689)
Evidence considered
  • ClinGen InSiGHT APC VCEP CSPEC BS3 Supporting rule: qualifying evidence requires no mRNA aberration in the specified RNA context or retention of beta-catenin-regulated transcription activity comparable to wild type, with the protein path restricted to APC codons 959-2129.
  • Case normalization identifies NM_001127510.3:c.8462A>G as NP_001120982.1:p.(Asp2821Gly), a missense variant in exon 17, codon 2821.
  • APC_specifications_supplementary-material_V2.pdf.txt was searched for c.8462A>G, p.Asp2821Gly, and p.D2821G; no matching variant entry was found.
  • PMID:25741868 paper extract: no APC c.8462A>G or p.(D2821G) and no variant-specific functional result.
  • PMID:26580448 paper extract: no explicit mention of APC c.8462A>G or p.(D2821G) and no variant-specific functional assay or benign functional result.
Still missing
  • No entry for c.8462A>G, p.Asp2821Gly, or p.D2821G was found in APC_specifications_supplementary-material_V2.pdf.txt.
  • No variant-specific qualifying RNA assay or protein assay demonstrating retained function was identified in the available evidence or paper extracts.
Sources
BS4 VCEPNot assessed: no affected non-carrier or qualifying phenotype-point score is documented for this variant. Details ▾Hide ▴
Reasoning

The APC VCEP requires an affected member without the variant and a qualifying phenotype-point score for BS4. The available case evidence contains no affected non-carrier, phenotype-point assignment, family genotype comparison, or non-segregation observation for NM_001127510.3:c.8462A>G (p.Asp2821Gly; p.D2821G). The VCEP files contain no variant-specific entry under any of the searched notations. BS4 cannot therefore be evaluated under the VCEP rule.

VCEP rule
Affected member without the variant must score at least 1 phenotype point or at least two affected members without the variant must each score at least 0.5 phenotype points (see **Table 1**). ... Affected member without the variant must score at least 0.5 phenotype points (see **Table 1**).
Evidence considered
  • The case bundle contains no affected non-carrier, phenotype-point score, family genotype comparison, or non-segregation observation for NM_001127510.3:c.8462A>G.
  • APC_specifications_supplementary-material_V2.pdf.txt was searched for c.8462A>G, p.Asp2821Gly, and p.D2821G; no variant-specific entry was found.
  • Table-1%262.pdf.txt was searched for c.8462A>G, p.Asp2821Gly, and p.D2821G; no variant-specific entry was found.
Still missing
  • No affected family member without the variant is documented.
  • No phenotype-point score for an affected non-carrier is documented.
  • No family genotype comparison or non-segregation observation is documented.
  • No entry for c.8462A>G, p.Asp2821Gly, or p.D2821G was found in APC_specifications_supplementary-material_V2.pdf.txt.
  • No entry for c.8462A>G, p.Asp2821Gly, or p.D2821G was found in Table-1%262.pdf.txt.
Sources
BP2 VCEPNot assessed: no documented trans phase or at least three unknown-phase observations with different (Likely) Pathogenic APC variants are available. Details ▾Hide ▴
Reasoning

BP2 is applicable under the APC VCEP specification, but the available case evidence does not document this variant observed in trans with a (Likely) Pathogenic APC variant and does not document at least three observations in an unknown phase with different (Likely) Pathogenic APC variants. The available literature extraction does not mention NM_001127510.3:c.8462A>G or provide phase, affected-proband, cis/trans, or inheritance observations for this variant. Because the VCEP rule cannot be evaluated from the available evidence, BP2 is not_assessed rather than not_met.

VCEP rule
Observed _in trans_ with a (Likely) Pathogenic _APC_ variant **OR** ≥ 3 times in an unknown phase with different (Likely) Pathogenic _APC_ variants.
Evidence considered
  • ClinGen InSiGHT APC specification v2.1, CSPEC PM3/BP2 criterion entry: BP2 requires observation in trans with a (Likely) Pathogenic APC variant or at least 3 observations in unknown phase with different (Likely) Pathogenic APC variants.
  • The case literature extraction for PMID:26580448 reports APC mutations in six pediatric cancer patients but does not mention c.8462A>G/p.(D2821G) and provides no variant-specific phase, cis/trans, affected-proband, or inheritance data.
  • The case literature extraction for PMID:25741868 is a general ACMG/AMP framework and does not provide variant-specific APC c.8462A>G/p.(D2821G) phase or inheritance evidence.
Still missing
  • Documented phase with a (Likely) Pathogenic APC variant, or at least three observations with different (Likely) Pathogenic APC variants in unknown phase, is unavailable.
Sources
BP5 VCEPNot assessed: no alternate pathogenic polyposis-gene variant and qualifying colorectal polyposis phenotype are documented for this case. Details ▾Hide ▴
Reasoning

The APC VCEP permits BP5 only when a (Likely) Pathogenic variant in another specified adenomatous polyposis gene is identified and a colorectal polyposis phenotype is present. The available case evidence does not document such an alternate pathogenic variant or establish the required colorectal polyposis phenotype, so the rule cannot be evaluated.

VCEP rule
Only applicable for an alternate genetic basis of the colorectal polyposis phenotype.
Evidence considered
  • APC_specifications_supplementary-material_V2.pdf, BP5 row: BP5 can be used if a (Likely) Pathogenic variant in another adenomatous polyposis gene is identified, and only when a colorectal polyposis phenotype is present.
  • APC VCEP CSPEC BP5 strength rule: "Only applicable for an alternate genetic basis of the colorectal polyposis phenotype."
  • The case bundle contains no documented alternate pathogenic polyposis-gene result or qualifying colorectal polyposis phenotype for this criterion.
Still missing
  • No documented (Likely) Pathogenic variant in another APC VCEP-listed adenomatous polyposis gene.
  • No case-level documentation establishing the required colorectal polyposis phenotype.
Sources
Not applicable · 11· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: c.8462A>G is a missense SNV, whereas APC PVS1 applies to null variants such as nonsense, frameshift, canonical splice-site, initiation-codon, or exon-deletion variants. Details ▾Hide ▴
Reasoning

PVS1 is not applicable because NM_001127510.3:c.8462A>G (p.Asp2821Gly/p.D2821G) is a missense SNV in exon 17, not a null variant of the types named by the APC VCEP rule. The APC PVS1 decision-tree file was searched for c.8462A>G, p.Asp2821Gly, and p.D2821G; no exact entry was found. The variant is therefore outside the VCEP-defined PVS1 variant classes, irrespective of APC's established LOF disease mechanism.

VCEP rule
Null variant (nonsense, frameshift, canonical +/-1 or 2 splice sites, initiation codon, single or multi-exon deletion) in a gene where loss of function (LOF) is a known mechanism of disease ... APC is a gene where LOF is the predominant mechanism of disease.
Evidence considered
  • Case variant assessment: NM_001127510.3:c.8462A>G, NP_001120982.1:p.(Asp2821Gly)/p.(D2821G), exon 17, consequence class missense, canonical splice consensus false.
  • APC_specifications_supplementary-material_V2.pdf, PVS1 row: the original criterion is limited to null variants (nonsense, frameshift, canonical +/-1 or 2 splice sites, initiation codon, or single/multi-exon deletion) in a gene where LOF is a known mechanism; the APC VCEP states that LOF is the predominant mechanism of disease.
  • Fig.-1_APC_PVS1_decision-tree_2023-10-20.pdf, List A-E table: searched for c.8462A>G, p.Asp2821Gly, and p.D2821G; no matching row was present.
Still missing
  • No exact c.8462A>G, p.Asp2821Gly, or p.D2821G entry was found in Fig.-1_APC_PVS1_decision-tree_2023-10-20.pdf.txt.
Sources
PM1 VCEPNot applicable: the APC VCEP identifies no approved PM1 hotspot or critical-domain route beyond residues 1026 and 1028, while this variant is at residue 2821. Details ▾Hide ▴
Reasoning

The APC VCEP CSPEC marks PM1 Not Applicable. Its governing text identifies only residues 1026 and 1028 as positions with APC-specific Likely Pathogenic missense evidence, states that these do not yet establish a mutational hotspot, and states that there are no other known pathogenic missense germline hotspots in APC. The case residue is 2821, and vcep_materials.json has no domain_tables entry supplying an alternative approved domain route.

VCEP rule
Based on our knowledge there are only two amino acid positions (1026 and 1028), where reported missense variants can be classified as Likely Pathogenic based on the APC-specific criteria (c.3077A>G p.(Asn1026Ser) and c.3084T>A p.(Ser1028Arg)) (for details see PS1). However, until now there is not enough evidence to define this as a mutational hotspot. There are no other known mutational hotspots for pathogenic missense germline variants in APC.
Evidence considered
  • APC VCEP CSPEC applicability: PM1 is Not Applicable.
  • APC VCEP PM1 text: only residues 1026 and 1028 have reported missense variants classifiable as Likely Pathogenic under APC-specific criteria; there is not enough evidence to define these as a mutational hotspot; there are no other known mutational hotspots for pathogenic missense germline variants in APC.
  • The authoritative APC domain_tables object is empty, so no additional approved functional-domain entry covers residue 2821.
Still missing
  • No entry for c.8462A>G, p.Asp2821Gly, or p.D2821G was found in APC_specifications_supplementary-material_V2.pdf.txt.
  • vcep_materials.json domain_tables is empty for APC.
Sources
PM3 VCEPNot applicable: the APC VCEP does not use PM3 because familial adenomatous polyposis has autosomal dominant inheritance. Details ▾Hide ▴
Reasoning

PM3 is not applicable under the APC VCEP specification. The VCEP states that PM3 is not used because familial adenomatous polyposis has an autosomal dominant mode of inheritance; therefore, phase and affected-proband observations cannot activate PM3 for this APC interpretation.

VCEP rule
Not used as FAP has an autosomal dominant mode of inheritance.
Evidence considered
  • ClinGen InSiGHT APC specification v2.1, APC_specifications_supplementary-material_V2.pdf, page 4, PM3 row: PM3 is not used because FAP has an autosomal dominant mode of inheritance.
Sources
PM4 VCEPNot applicable: the APC VCEP states PM4 is not used due to limited available data, and this variant is a missense SNV rather than a protein-length change. Details ▾Hide ▴
Reasoning

PM4 is not applicable under the APC VCEP specification: the PM4 row states that it is not used due to limited available data. The variant is also a missense SNV and does not produce an in-frame deletion/insertion or a stop-loss protein-length change.

VCEP rule
Not used due to limited available data.
Evidence considered
  • APC_specifications_supplementary-material_V2.pdf, PM4 row: criterion concerns protein-length changes from in-frame deletions/insertions in a non-repeat region or stop-loss variants; APC VCEP comment is 'Not used due to limited available data.'
  • Case variant assessment: c.8462A>G is a missense SNV causing p.Asp2821Gly, not an in-frame deletion/insertion or stop-loss variant.
Sources
PP2 VCEPNot applicable: the APC VCEP marks PP2 unusable because missense variants are uncommon and usually benign, likely benign, or VUS in APC. Details ▾Hide ▴
Reasoning

The APC VCEP CSPEC explicitly marks PP2 Not Applicable. The VCEP explains that missense variants are not a frequent mutation type in APC, most are benign, likely benign, or VUS, and only two positions have reported Likely Pathogenic missense variants. PP2 therefore cannot be applied to this missense variant.

VCEP rule
Missense variants are not a frequent mutation type in APC. The majority of missense variants are regarded as benign / likely benign or VUS in ClinVar / LOVD. A few represent splice variants (Karabachev et al. 2020, PMID: 32750050) and low/moderate penetrant variants. Currently, there are only two amino acid positions with reported Likely Pathogenic missense variants (p.Asn1026 and p.Ser1028) (for details see PS1).
Evidence considered
  • APC VCEP CSPEC applicability: PP2 is Not Applicable.
  • APC VCEP PP2 comment: missense variants are not a frequent mutation type in APC; the majority are regarded as benign, likely benign, or VUS in ClinVar or LOVD; only positions 1026 and 1028 have reported Likely Pathogenic missense variants.
Still missing
  • No entry for c.8462A>G, p.Asp2821Gly, or p.D2821G was found in APC_specifications_supplementary-material_V2.pdf.txt.
Sources
PP4 VCEPNot applicable: the APC VCEP explicitly disallows PP4 as independent evidence because phenotype evidence is captured by PS4. Details ▾Hide ▴
Reasoning

The APC VCEP states that PP4 is already captured by PS4 specifications and cannot be used as independent evidence.

VCEP rule
Already captured by the specifications of PS4, and thus cannot be used as independent evidence.
Evidence considered
  • APC_specifications_supplementary-material_V2.pdf, PP4 row: "Already captured by the specifications of PS4, and thus cannot be used as independent evidence."
Sources
PP5 VCEPNot applicable: the APC VCEP does not use PP5 when a reputable report lacks independently evaluable primary evidence. Details ▾Hide ▴
Reasoning

The APC VCEP marks PP5 as not used, following the recommendation that expert opinions should be considered only when accompanied by the primary evidence used.

VCEP rule
Not used as recommended by Biesecker et al. 2018 (PMID: 29543229): Expert opinions should only be considered if accompanied by the primary evidence used.
Evidence considered
  • APC_specifications_supplementary-material_V2.pdf, PP5 row: "Not used as recommended by Biesecker et al. 2018 (PMID: 29543229): Expert opinions should only be considered if accompanied by the primary evidence used."
  • literature_pass.json has no ai_classified_papers and the available paper extract for PMID:26580448 does not report this exact variant.
Sources
BP3 VCEPNot applicable: the APC VCEP explicitly states BP3 is not used due to limited available data, and c.8462A>G is a missense SNV. Details ▾Hide ▴
Reasoning

BP3 is not applicable under the APC VCEP specification. The BP3 row explicitly states that the APC VCEP does not use this criterion due to limited available data; the variant's missense SNV consequence also does not match the in-frame deletion/insertion context associated with BP3.

VCEP rule
APC VCEP: Not used due to limited available data.
Evidence considered
  • APC_specifications_supplementary-material_V2.pdf, BP3 row: 'APC VCEP: Not used due to limited available data.'
  • Case variant assessment: c.8462A>G is a missense SNV causing p.Asp2821Gly.
Sources
BP4 N/ANot applicable: the APC VCEP explicitly excludes missense variants from BP4, and p.(Asp2821Gly) is missense. Details ▾Hide ▴
Reasoning

The APC VCEP explicitly states that BP4 is not applicable for missense variants. This variant is a missense SNV, p.(Asp2821Gly), so BP4 is outside its governing scope regardless of the SpliceAI result.

VCEP rule
**Missense variants:** BP4 is not applicable. **Synonymous (silent) or intronic variants**: Multiple in silico splicing predictors suggest no impact on gene or gene product.
Evidence considered
  • Case variant normalization and consequence: NM_001127510.3:c.8462A>G, NP_001120982.1:p.(Asp2821Gly), VEP consequence missense_variant.
  • APC_specifications_supplementary-material_V2.pdf, BP4 section: the VCEP states, "BP4 is not applicable for missense variants."
Still missing
  • The APC_specifications_supplementary-material_V2.pdf file was searched for c.8462A>G, p.Asp2821Gly, and p.D2821G; no variant-specific entry was found.
Sources
BP6 VCEPNot applicable: the APC VCEP explicitly does not use BP6 for unsupported reputable-source benign reports. Details ▾Hide ▴
Reasoning

The APC VCEP marks BP6 as not used and states that expert opinions should be considered only when accompanied by the primary evidence used.

VCEP rule
Not used as recommended by Biesecker et al. 2018 (PMID: 29543229): Expert opinions should only be considered if accompanied by the primary evidence used.
Evidence considered
  • APC_specifications_supplementary-material_V2.pdf, BP6 row: "Not used as recommended by Biesecker et al. 2018 (PMID: 29543229): Expert opinions should only be considered if accompanied by the primary evidence used."
Sources
BP7 N/ANot applicable: BP7 is restricted to synonymous or intronic variants, whereas c.8462A>G causes the missense change p.(Asp2821Gly). Details ▾Hide ▴
Reasoning

The APC VCEP BP7 rule applies to synonymous or intronic variants at or beyond specified splice-distance positions. This variant is a coding missense SNV producing p.(Asp2821Gly), not a synonymous or intronic variant, so BP7 is outside its governing scope.

VCEP rule
A synonymous (silent) or intronic variant at or beyond +7/−21 for which multiple splicing prediction algorithms predict no impact to the splice consensus sequence nor the creation of a new splice site.
Evidence considered
  • Case variant normalization and consequence: NM_001127510.3:c.8462A>G, NP_001120982.1:p.(Asp2821Gly), VEP consequence missense_variant.
  • APC_specifications_supplementary-material_V2.pdf, BP7 section: the criterion is defined for a synonymous (silent) variant and the APC modification notes that the rule covers synonymous and intronic variants without requiring a conservation prediction.
Still missing
  • The APC_specifications_supplementary-material_V2.pdf file was searched for c.8462A>G, p.Asp2821Gly, and p.D2821G; no variant-specific entry was found.
Sources

Identifiers

Gene
APC
Transcript
NM_001127510.3
Coding (HGVS c.)
NM_001127510.3:c.8462A>G
Protein (HGVS p.)
NP_001120982.1:p.(Asp2821Gly)
GRCh38
chr5:112844056 A>G
GRCh37
chr5:112179753 A>G
Location and type
Exon 17 · missense
ClinVar
1491735, 216188
COSMIC
COSV57360049

Gene diagram

Every interpreted variant in APC, mapped onto the exon structure of NM_001127510.3. Select a row to find it on the plot.

APCNM_001127510.3
Fetching transcript structure from UCSC…
gnomAD v4.1 50 / 1,604,312 alleles AF 3.12e-05 · 0 homozygotes · FAF 0.000418
gnomAD v2.1 10 / 271,548 alleles AF 3.68e-05 · 0 homozygotes · FAF 0.000204
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 3.1e-05 · 50 / 1,604,312 alleles · 0 hom · FAF 0.00042
African/African American41 / 74,122 0.00055
Remaining individuals5 / 61,954 8.1e-05
Admixed American3 / 57,232 5.2e-05
European (non-Finnish)1 / 1,177,698 8.5e-07
0 alternate alleles recorded in 6 other groups: European (Finnish), Amish, East Asian, Middle Eastern, South Asian, Ashkenazi Jewish.

gnomAD v2.1

AF 3.7e-05 · 10 / 271,548 alleles · 0 hom · FAF 0.0002
African/African American9 / 24,748 0.00036
European (non-Finnish)1 / 125,704 8e-06
0 alternate alleles recorded in 6 other groups: Admixed American, Ashkenazi Jewish, East Asian, European (Finnish), Remaining individuals, South Asian.

gnomAD-Canada

AF not recorded · ? / ? alleles

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 3.1166e-05; MAF= 0.00312%, 50/1604312 alleles, homozygotes = 0) and has highest observed frequency in the African/African American population (AF= 0.000553142; MAF= 0.05531%, 41/74122 alleles, homozygotes = 0); grpmax FAF= 0.00041823.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 3.68259e-05; MAF= 0.00368%, 10/271548 alleles, homozygotes = 0) and has highest observed frequency in the African/African American population (AF= 0.000363666; MAF= 0.03637%, 9/24748 alleles, homozygotes = 0); grpmax FAF= 0.00020406.

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 0.00010857763300760044, 2/18420 alleles, homozygotes = 0).

Open the gnomAD-Canada detail page →

SpliceAI and Pangolin

SpliceAI acceptor lossat -280 bp
0.000
SpliceAI acceptor gainat -95 bp
0.000
SpliceAI donor lossat -31 bp
0.000
SpliceAI donor gainat +14 bp
0.000
Pangolin splice lossmagnitude shown
-0.006
Pangolin splice gain
0.006

Other predictors

REVEL
0.226
BayesDel
-0.172

How the predictions were used

PP3 VCEPNot assessed: SpliceAI max delta score is 0.00, but the VCEP-directed multi-predictor splice evaluation lacks a MaxEntScan result. Details ▾Hide ▴
Reasoning

The APC VCEP limits missense computational evidence by excluding conservation/evolutionary models and directing use of in silico splicing predictors for presumed missense variants. The variant is a missense SNV, NM_001127510.3:c.8462A>G, p.(Asp2821Gly), so PP3 is within scope only for possible splice impact. The available SpliceAI result has DS_AG=0.00, DS_AL=0.00, DS_DG=0.00, DS_DL=0.00 and max delta score=0.00, which does not support a deleterious splice effect. However, the APC supplementary material identifies SpliceAI and MaxEntScan as the recommended splice prediction programs and the available case evidence contains no MaxEntScan result or multiple-predictor deleterious result. Therefore the VCEP computational splice-evidence requirement cannot be fully evaluated; no missense protein-impact predictor was used because the VCEP excludes those models for this purpose.

VCEP rule
**Missense variants:** Do not use computational prediction models for conservation, evolution, etc. _In silico_ splicing predictors should be used for presumed missense variants to reveal possible splicing effects.
Evidence considered
  • APC VCEP PP3 rule in cspec: for missense variants, do not use conservation/evolutionary computational models; use in silico splicing predictors for presumed missense variants to reveal possible splicing effects.
  • Case variant normalization: NM_001127510.3:c.8462A>G, NP_001120982.1:p.(Asp2821Gly), VEP consequence missense_variant.
  • SpliceAI Lookup result for NM_001127510.3:c.8462A>G: DS_AG=0.00, DS_AL=0.00, DS_DG=0.00, DS_DL=0.00, max delta score=0.00; the result predicts no significant splice impact.
  • APC_specifications_supplementary-material_V2.pdf, PP3 section and footnote 1: the VCEP directs use of splice prediction programs, including SpliceAI and MaxEntScan; only SpliceAI is available in the case evidence.
Still missing
  • The APC_specifications_supplementary-material_V2.pdf file was searched for c.8462A>G, p.Asp2821Gly, and p.D2821G; no variant-specific entry was found.
  • No MaxEntScan result or other second VCEP-recommended splice-predictor result is available for this variant.
Sources
BP4 N/ANot applicable: the APC VCEP explicitly excludes missense variants from BP4, and p.(Asp2821Gly) is missense. Details ▾Hide ▴
Reasoning

The APC VCEP explicitly states that BP4 is not applicable for missense variants. This variant is a missense SNV, p.(Asp2821Gly), so BP4 is outside its governing scope regardless of the SpliceAI result.

VCEP rule
**Missense variants:** BP4 is not applicable. **Synonymous (silent) or intronic variants**: Multiple in silico splicing predictors suggest no impact on gene or gene product.
Evidence considered
  • Case variant normalization and consequence: NM_001127510.3:c.8462A>G, NP_001120982.1:p.(Asp2821Gly), VEP consequence missense_variant.
  • APC_specifications_supplementary-material_V2.pdf, BP4 section: the VCEP states, "BP4 is not applicable for missense variants."
Still missing
  • The APC_specifications_supplementary-material_V2.pdf file was searched for c.8462A>G, p.Asp2821Gly, and p.D2821G; no variant-specific entry was found.
Sources
BP7 N/ANot applicable: BP7 is restricted to synonymous or intronic variants, whereas c.8462A>G causes the missense change p.(Asp2821Gly). Details ▾Hide ▴
Reasoning

The APC VCEP BP7 rule applies to synonymous or intronic variants at or beyond specified splice-distance positions. This variant is a coding missense SNV producing p.(Asp2821Gly), not a synonymous or intronic variant, so BP7 is outside its governing scope.

VCEP rule
A synonymous (silent) or intronic variant at or beyond +7/−21 for which multiple splicing prediction algorithms predict no impact to the splice consensus sequence nor the creation of a new splice site.
Evidence considered
  • Case variant normalization and consequence: NM_001127510.3:c.8462A>G, NP_001120982.1:p.(Asp2821Gly), VEP consequence missense_variant.
  • APC_specifications_supplementary-material_V2.pdf, BP7 section: the criterion is defined for a synonymous (silent) variant and the APC modification notes that the rule covers synonymous and intronic variants without requiring a conservation prediction.
Still missing
  • The APC_specifications_supplementary-material_V2.pdf file was searched for c.8462A>G, p.Asp2821Gly, and p.D2821G; no variant-specific entry was found.
Sources

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00). REVEL score = 0.226. BayesDel score = -0.172157.

8 paper records listed. No publication is explicitly linked to an applied criterion in the recorded metadata. None of the listed paper records explicitly indicates that the variant is named.

Recorded publications

  • ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.
    Schmoll HJ et al. · 2012
    No paper-specific finding is recorded.
    PMID 23012255 ↗
  • Recommendations from the EGAPP Working Group: can testing of tumor tissue for mu
    No paper-specific finding is recorded.
    PMID 23429431 ↗
  • ACMG technical standards and guidelines for genetic testing for inherited colore
    No paper-specific finding is recorded.
    PMID 24310308 ↗
  • A practice guideline from the American College of Medical Genetics and Genomics
    No paper-specific finding is recorded.
    PMID 25394175 ↗
  • Standards and guidelines for the interpretation of sequence variants: a joint co
    This paper does not mention APC c.8462A>G or NP_001120982.1:p.(D2821G) and provides no variant-specific functional results; it is a general ACMG/AMP framework rather than an APC-specific functional study.
    Does not name this variant
    PMID 25741868 ↗
    Quoted passage
    The variant classification approach described in this paper is meant to be applicable to variants in all Mendelian genes.

    Proposed Criteria for Interpretation of Sequence Variants, paragraph 1

  • Germline Mutations in Predisposition Genes in Pediatric Cancer.
    Zhang J et al. · 2015
    This paper does not explicitly mention APC c.8462A>G or p.(D2821G). It reports APC among the autosomal-dominant cancer-predisposition genes analyzed, but provides no variant-specific de novo observation, parental testing, segregation analysis, affected non-carrier comparison, or population-frequency result for this variant.
    Does not name this variant
    PMID 26580448 ↗
    Quoted passage
    The 95 variants that were deemed to be pathogenic or probably pathogenic were detected in 21 of the 60 genes in 94 patients (Fig. 3A, and Fig. S3 in Supplementary Appendix 1). TP53 was most commonly involved (in 50 patients), followed by APC (in 6), BRCA2 (in 6), NF1 (in 4), PMS2 (in 4), RB1 (in 3), and RUNX1 (in 3).

    Results, Germline Mutations in Cancer-Predisposition Genes; Correlation between Germline Genotype and Tumor Phenotype; Medical and Family History

  • Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
    Tung N et al. · 2016
    No paper-specific finding is recorded.
    PMID 26976419 ↗
  • Sherloc: a comprehensive refinement of the ACMG-AMP variant classification crite
    No paper-specific finding is recorded.
    PMID 28492532 ↗

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 3.1166e-05; MAF= 0.00312%, 50/1604312 alleles, homozygotes = 0) and has highest observed frequency in the African/African American population (AF= 0.000553142; MAF= 0.05531%, 41/74122 alleles, homozygotes = 0); grpmax FAF= 0.00041823.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 3.68259e-05; MAF= 0.00368%, 10/271548 alleles, homozygotes = 0) and has highest observed frequency in the African/African American population (AF= 0.000363666; MAF= 0.03637%, 9/24748 alleles, homozygotes = 0); grpmax FAF= 0.00020406.

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 0.00010857763300760044, 2/18420 alleles, homozygotes = 0).

ClinVar

This variant has been reported in ClinVar as Likely benign (7 clinical laboratories) and as Uncertain significance (2 clinical laboratories) and as Uncertain Significance (1 clinical laboratory) and as Benign (1 clinical laboratory). (ClinVarID = 216188)

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00). REVEL score = 0.226. BayesDel score = -0.172157.

Functional

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has previously been reported in somatic cancers (COSMIC; COSV57360049, n = 1 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.